SG10201902765VA - C. novyi for the treatment of solid tumors in humans - Google Patents
C. novyi for the treatment of solid tumors in humansInfo
- Publication number
- SG10201902765VA SG10201902765VA SG10201902765VA SG10201902765VA SG10201902765VA SG 10201902765V A SG10201902765V A SG 10201902765VA SG 10201902765V A SG10201902765V A SG 10201902765VA SG 10201902765V A SG10201902765V A SG 10201902765VA SG 10201902765V A SG10201902765V A SG 10201902765VA
- Authority
- SG
- Singapore
- Prior art keywords
- human
- novyi
- methods
- solid tumor
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
Abstract
C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a human. These methods include administering intratumorally to the human a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1 x 10 3-1 x 10 7 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a human, methods for ablating a solid tumor present in a human, a method for microscopically precise excision of tumor cells in a human, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a human, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a human are also provided. FIGURE 2A
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361806497P | 2013-03-29 | 2013-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201902765VA true SG10201902765VA (en) | 2019-04-29 |
Family
ID=51625539
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201508071VA SG11201508071VA (en) | 2013-03-29 | 2014-03-28 | C. novyi for the treatment of solid tumors in humans |
SG10201902765VA SG10201902765VA (en) | 2013-03-29 | 2014-03-28 | C. novyi for the treatment of solid tumors in humans |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201508071VA SG11201508071VA (en) | 2013-03-29 | 2014-03-28 | C. novyi for the treatment of solid tumors in humans |
Country Status (20)
Country | Link |
---|---|
US (3) | US10617723B2 (en) |
EP (3) | EP2988760B1 (en) |
JP (6) | JP6756609B2 (en) |
KR (1) | KR20160021084A (en) |
CN (2) | CN105451750B (en) |
AU (2) | AU2014240872A1 (en) |
BR (2) | BR122020006408B1 (en) |
CA (2) | CA3206655A1 (en) |
DK (1) | DK2988760T3 (en) |
ES (2) | ES2922378T3 (en) |
HK (1) | HK1222134A1 (en) |
IL (1) | IL241823B (en) |
MX (1) | MX2015013784A (en) |
NZ (1) | NZ712691A (en) |
PH (1) | PH12015502260A1 (en) |
RU (1) | RU2718670C2 (en) |
SG (2) | SG11201508071VA (en) |
UA (1) | UA120036C2 (en) |
WO (1) | WO2014160950A1 (en) |
ZA (2) | ZA201507412B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2944456C (en) * | 2014-03-31 | 2023-10-31 | The Johns Hopkins University | Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies |
CN105912930B (en) * | 2016-04-11 | 2019-02-01 | 北京奇虎科技有限公司 | Mobile terminal and its system resource method of controlling security |
US10815534B2 (en) | 2016-08-23 | 2020-10-27 | Mayo Foundation For Medical Education And Research | Methods and materials for treating estrogen receptor positive breast cancer |
AU2018269982A1 (en) * | 2017-05-16 | 2020-01-02 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating cancer with atypical BRAF mutations |
CN109985039A (en) * | 2017-12-29 | 2019-07-09 | 深圳微芯生物科技股份有限公司 | For treating the combination medicine of leukaemia and its preparing the purposes in the drug for treating acute myeloid leukaemia |
WO2021231611A1 (en) * | 2020-05-12 | 2021-11-18 | Splash Pharmaceuticals, Inc. | Methods for treating cancer using spl-108 polypeptide based on tp53 mutational status |
US11717787B2 (en) * | 2021-01-04 | 2023-08-08 | Saudi Arabian Oil Company | High free volume membrane for gas separation |
CN113855710B (en) * | 2021-10-09 | 2024-02-20 | 施慧达药业集团(吉林)有限公司 | Application of clostridium gossypii combined tumor angiogenesis inhibitor |
CN115350145A (en) * | 2022-09-06 | 2022-11-18 | 华中科技大学同济医学院附属协和医院 | Application of bacteria-mediated metformin-loaded polypeptide hydrogel in tumor immunotherapy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599331A (en) | 1984-12-24 | 1986-07-08 | Syntex (U.S.A.) Inc. | Etianic acids as antiangiogenics |
EP0221705A1 (en) | 1985-10-23 | 1987-05-13 | The Upjohn Company | Tetrahydro angiostatic steroids |
US4771042A (en) | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
EP0477195A1 (en) | 1989-06-16 | 1992-04-01 | The Upjohn Company | Suramin type compounds and angiostatic steroids to inhibit angiogenesis |
CA2425841C (en) | 1991-11-22 | 2006-01-10 | Alcon Laboratories, Inc. | Angiostatic steroids |
WO2002067796A1 (en) | 2001-02-28 | 2002-09-06 | Rex Medical, L.P. | Apparatus for delivering ablation fluid to treat neoplasms |
EP1446012B1 (en) * | 2001-11-21 | 2013-07-17 | The Johns Hopkins University | Combination bacteriolytic therapy for the treatment of tumors |
WO2005018332A1 (en) * | 2003-08-13 | 2005-03-03 | The General Hospital Corporation | Modified microorganisms for anti-cancer therapy |
EP1675465B1 (en) | 2003-10-22 | 2010-03-03 | The Johns Hopkins University | Improved combination bacteriolytic therapy for the treatment of tumors |
US20070015738A1 (en) * | 2005-07-15 | 2007-01-18 | Walker Stephen G | Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells |
TW200819540A (en) * | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
-
2014
- 2014-03-28 CA CA3206655A patent/CA3206655A1/en active Pending
- 2014-03-28 EP EP14774988.1A patent/EP2988760B1/en active Active
- 2014-03-28 JP JP2016505594A patent/JP6756609B2/en active Active
- 2014-03-28 AU AU2014240872A patent/AU2014240872A1/en not_active Abandoned
- 2014-03-28 NZ NZ712691A patent/NZ712691A/en unknown
- 2014-03-28 BR BR122020006408-0A patent/BR122020006408B1/en active IP Right Grant
- 2014-03-28 DK DK14774988.1T patent/DK2988760T3/en active
- 2014-03-28 US US14/781,273 patent/US10617723B2/en active Active
- 2014-03-28 MX MX2015013784A patent/MX2015013784A/en active IP Right Grant
- 2014-03-28 EP EP22171112.0A patent/EP4108248A1/en active Pending
- 2014-03-28 CA CA2908508A patent/CA2908508C/en active Active
- 2014-03-28 WO PCT/US2014/032196 patent/WO2014160950A1/en active Application Filing
- 2014-03-28 CN CN201480028119.8A patent/CN105451750B/en active Active
- 2014-03-28 SG SG11201508071VA patent/SG11201508071VA/en unknown
- 2014-03-28 ES ES20167187T patent/ES2922378T3/en active Active
- 2014-03-28 CN CN202310166182.9A patent/CN116570628A/en active Pending
- 2014-03-28 RU RU2015146199A patent/RU2718670C2/en active
- 2014-03-28 BR BR112015024621-4A patent/BR112015024621B1/en active IP Right Grant
- 2014-03-28 SG SG10201902765VA patent/SG10201902765VA/en unknown
- 2014-03-28 UA UAA201510523A patent/UA120036C2/en unknown
- 2014-03-28 EP EP20167187.2A patent/EP3730146B1/en active Active
- 2014-03-28 ES ES14774988T patent/ES2815564T3/en active Active
- 2014-03-28 KR KR1020157031284A patent/KR20160021084A/en not_active Application Discontinuation
-
2015
- 2015-09-24 IL IL241823A patent/IL241823B/en active IP Right Grant
- 2015-09-29 PH PH12015502260A patent/PH12015502260A1/en unknown
- 2015-10-06 ZA ZA2015/07412A patent/ZA201507412B/en unknown
-
2016
- 2016-09-01 HK HK16110438.1A patent/HK1222134A1/en unknown
-
2017
- 2017-02-14 JP JP2017025263A patent/JP2017088619A/en active Pending
- 2017-09-21 ZA ZA2017/06402A patent/ZA201706402B/en unknown
-
2018
- 2018-10-26 JP JP2018201792A patent/JP2019011376A/en active Pending
-
2019
- 2019-01-17 AU AU2019200276A patent/AU2019200276B2/en active Active
-
2020
- 2020-03-31 US US16/836,003 patent/US11439669B2/en active Active
- 2020-06-25 JP JP2020109387A patent/JP7445893B2/en active Active
-
2021
- 2021-12-09 JP JP2021199949A patent/JP2022022392A/en active Pending
-
2022
- 2022-08-02 US US17/816,924 patent/US20220378852A1/en active Pending
-
2024
- 2024-03-06 JP JP2024034039A patent/JP2024056012A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502260A1 (en) | C. novyi for the treatment of solid tumors in humans | |
MX2021013830A (en) | Ezh2 inhibitors for treating lymphoma. | |
MX2021004821A (en) | Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy. | |
MX2018008426A (en) | Anti-egfr combinations for treating tumors. | |
SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
SG10201902664RA (en) | Combination therapy for treating cancer | |
PH12017550063A1 (en) | Combination therapies for treating cancers | |
MX2020003719A (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer. | |
MX2016007351A (en) | Combination therapy for treating cancer. | |
SG10201902594QA (en) | Peptidomimetic macrocycles and uses thereof | |
MX2019010601A (en) | Combination therapy for treating cancer. | |
BR112018008503A2 (en) | method for treating small cell lung cancer, method for treating a subject, method for selecting a subject with cancer | |
MX2018008427A (en) | Anti-cd20 combinations for treating tumors. | |
MX2015003643A (en) | Method of treating cancer. | |
SG10201810397SA (en) | Compounds for treating brain cancer | |
AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
WO2016043874A3 (en) | Combination therapy for treating cancer | |
MX2018007823A (en) | Bromodomain and extra-terminal protein inhibitor combination therapy. | |
MX2020001727A (en) | Combination therapy. | |
WO2014160967A3 (en) | C. novyi for the treatment of solid tumors in non-human animals | |
MX2019013862A (en) | Combination therapy. | |
MX2022014792A (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same. | |
MX2018010223A (en) | Combination therapy for treatment of ovarian cancer. | |
PH12020500666A1 (en) | Pladienolide compounds and their use | |
MX2021011529A (en) | Chiauranib for treatment of small cell lung cancer. |